Patents by Inventor Arati V. Rao

Arati V. Rao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT USING A GENETICALLY MODIFIED AUTOLOGOUS T CELL IMMUNOTHERAPY
    Publication number: 20240016844
    Abstract: Methods of treating cancer with a precision genome engineered NeoTCR Product are described herein.
    Type: Application
    Filed: June 9, 2023
    Publication date: January 18, 2024
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Bhamini Purandare, Stefanie Mandl-Cashman, Gregg D. Fine, Arati V. Rao, Todd Stallings-Schmitt, Mark Walter Frohlich, Alex Franzusoff
  • METHODS OF TREATMENT USING A GENETICALLY MODIFIED AUTOLOGOUS T CELL IMMUNOTHERAPY
    Publication number: 20210205363
    Abstract: Methods of treating cancer with a precision genome engineered NeoTCR Product are described herein.
    Type: Application
    Filed: November 16, 2020
    Publication date: July 8, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Bhamini Purandare, Stefanie Mandl-Cashman, Gregg D. Fine, Arati V. Rao, Todd Stallings-Schmitt, Mark Walter Frohlich, Alex Franzusoff
  • SYK inhibitors
    Patent number: 10111882
    Abstract: The application provides methods of treating or reducing thrombocytopenia, leukopenia, anemia, or neutropenia in a patient in need thereof, comprising the step of administering an effective amount of a compound selected from Compounds 1-6, disclosed herein.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: October 30, 2018
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Esteban M. Abella, Julie A. Di Paolo, Kathleen S. Keegan, Antonio Mario Querido Marcondes, Yang Pan, Arati V. Rao
  • SYK INHIBITORS
    Publication number: 20180071302
    Abstract: The application provides methods of treating or reducing thrombocytopenia, leukopenia, anemia, or neutropenia in a patient in need thereof, comprising the step of administering an effective amount of a compound selected from Compounds 1-6, disclosed herein.
    Type: Application
    Filed: September 14, 2017
    Publication date: March 15, 2018
    Inventors: Esteban M. Abella, Julie A. Di Paolo, Kathleen S. Keegan, Antonio Mario Querido Marcondes, Yang Pan, Arati V. Rao
  • SYK INHIBITORS
    Publication number: 20180071303
    Abstract: The application provides methods reducing the side effects of chemotherapy and radiotherapy, including, hematopoietic toxicity, anemia, myelosuppression, pancytopenia, thrombocytopenia, neutropenia, lymphopenia, leukopenia, stomatitis and alopecia. The application provides a method for increasing the number of, neutrophil counts and platelet counts in a patient in need thereof, comprising administering an effective of an inhibitor of spleen tyrosine kinase (SYKi). The present application provides methods for treating myelosuppresive disorders by the administration of a SYKi. In certain embodiments, the myelosuppression is induced by the administration of one or more myelosuppressive agents, for example, anti-cancer drugs. The present application provides methods for treating AML/ALL in a patient with 11q23/MLL abnormalities comprising the step of administering an effective amount of a SYKi to said patient.
    Type: Application
    Filed: September 14, 2017
    Publication date: March 15, 2018
    Inventors: Esteban M. Abella, Arati V. Rao, Antonio Mario Querido Marcondes